Home/Pipeline/COVID-19 Vaccine (BNT162b2)

COVID-19 Vaccine (BNT162b2)

COVID-19 Prevention

ApprovedCommercial

Key Facts

Indication
COVID-19 Prevention
Phase
Approved
Status
Commercial
Company

About BioNTech

BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.

View full company profile

Other COVID-19 Prevention Drugs

DrugCompanyPhase
COVID-19 Inactivated VaccineHualan Biological EngineeringApproved